TrovaGene Inc (NASDAQ: TROV) is having a great start to the trading session this morning, and for good reason. The company said that it will be providing a clinical update relatively soon, exciting investors and sending the stock screaming for the top. Today, we’ll talk about:
- The clinical update;
- what we’re seeing from TROV stock as a result; and
- what we’ll be watching for ahead.
TROV To Provide A Clinical Update
As mentioned above, Trovagene is having an incredibly strong start to the trading session this morning after announcing that it would be providing a clinical update soon. In a press release issued early this morning, the company said that it will provide an update on the Onvansertib clinical program.
TROV said that the update will be provided via live conference call and webcast on Wednesday, October 24 at 8:30 AM. The company said that the call will include key data from the ongoing Phase 1b clinical trials in Acute Myeloid Leukemia as well as Castration-Resistant Prostate Cancer.
If you would like to join the TROV conference call, simply call 1-877-270-2148 and ask to join the Trovagene call. The company also said that a Live audio recording of the conference will be simultaneously webcast and available at the company’s website, www.trovagene.com. Finally, a replay will become available approximately 2 hours after the initial call.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of Trovagene, the news proved to be overwhelmingly positive. After all, the clinical update is likely to show that the treatment is producing positive results. As a result, it’s not surprising to see that excited investors are working to push the stock upward in the market this morning. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currnetly (10:04), TROV is trading at $1.21 per share after a gain of $0.17 per share or 16.55% so far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on TROV. In particular, we’re interested in following the story surrounding the company’s continued work to develop Onvansertib and the clinical update that is just around the cornre. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!